Unknown

Dataset Information

0

High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma.


ABSTRACT: About 40% of patients with non-small cell lung cancer (NSCLC) have stage IV cancer at the time of diagnosis. The only viable treatment options for metastatic disease are systemic chemotherapy and immunotherapy. Nonetheless, chemoresistance remains a major cause of chemotherapy failure. New immunotherapeutic modalities such as anti-PD-1 immune checkpoint blockade have shown promise; however, response to such strategies is highly variable across patients. Here, we show that our unique poly(2-oxazoline)-based nanomicellar formulation (PM) of Resiquimod, an imidazoquinoline Toll-like receptor (TLR) 7/8 agonist, had a superior tumor inhibitory effect in a metastatic model of lung adenocarcinoma, relative to anti-PD-1 therapy or platinum-based chemotherapy. Investigation of the in vivo immune status following Resiquimod PM treatment showed that Resiquimod-based stimulation of antigen-presenting cells in the tumor microenvironment resulted in the mobilization of an antitumor CD8+ immune response. Our study demonstrates the promise of poly(2-oxazoline)-formulated Resiquimod for treating metastatic NSCLC.

SUBMITTER: Vinod N 

PROVIDER: S-EPMC7299629 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7999147 | biostudies-literature
| S-EPMC3534837 | biostudies-literature
| S-EPMC2884201 | biostudies-literature
| S-EPMC6415335 | biostudies-literature
| S-EPMC6787588 | biostudies-literature
| S-EPMC6433829 | biostudies-literature
| S-EPMC4479148 | biostudies-other
| S-EPMC3698124 | biostudies-literature
| S-EPMC8699692 | biostudies-literature
| S-EPMC6457192 | biostudies-literature